The utility of combinations of drugs directed at specific sites of the same target enzyme--ribonucleotide reductase as the model.
Ribonucleotide reductase is a key enzyme in DNA replication and, as such, has been a target for antitumor agents. This enzyme is composed of two nonidentical protein subunits which can be specifically and independently inhibited. Combinations of drugs directed at the effector-binding and non-heme iron subunits of ribonucleotide reductase resulted in the synergistic inhibition of L1210 cell growth and synergistic L1210 cell kill. These combinations included dAdo/EHNA/IMPY/Desferal; dAdo/EHNA/hydroxyurea/Desferal (the EHNA was required to protect dAdo from deamination while Desferal modulated the effects of IMPY or hydroxyurea); 2-F-araA/IMPY/Desferal and 2-F-2'-dAdo/IMPY/Desferal (EHNA was not required to protect 2-F-araA or 2-F-2'-dAdo from deamination); and dGuo/8-AGuo/IMPY/Desferal (8-AGuo was required to protect dGuo from phosphorolysis). Although thymidine alone inhibited L1210 cell growth, it was not possible to potentiate the effects of thymidine with the pyrimidine nucleoside phosphorylase inhibitors, acyclothymidine, 5-chlorouracil and 2,6-dihydroxypyridine. Combinations of drugs directed at the ribonucleotide reductase and DNA polymerase sites were studied for their effects on L1210 cell growth. With these combinations, no synergistic inhibition of L1210 cell growth was observed. The combinations of aphidicolin and IMPY/Desferal and aphidicolin and dAdo/EHNA inhibited L1210 cell growth in an additive manner; the combinations of IMPY/Desferal and BuAU or IMPY/Desferal and BuPdG resulted in antagonistic inhibition of L1210 cell growth. From these results it is clear that combination chemotherapy directed at independent sites of the same key target enzyme can result in strong synergistic inhibition of cell growth and cytotoxicity offering a clear therapeutic advantage. In contrast, the combinations directed at sequential key enzymes (e.g. ribonucleotide reductase and DNA polymerase) did not result in synergistic inhibition of cell growth. The utility of combinations of drugs directed at specific but independent sites of the target enzyme (e.g. ribonucleotide reductase) has been demonstrated in tumor cell systems in culture and now must be demonstrated in vivo.
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology* / Q000627:therapeutic use; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D003839:Deoxyadenosines / Q000031:analogs & derivatives / Q000494:pharmacology; D003849:Deoxyguanosine / Q000494:pharmacology; D006918:Hydroxyurea / Q000494:pharmacology; D007546:Isoquinolines / Q000494:pharmacology; D007939:Leukemia L1210 / Q000188:drug therapy* / Q000473:pathology; D008954:Models, Biological; D019384:Nucleic Acid Synthesis Inhibitors; D006005:Phosphorylases / Q000037:antagonists & inhibitors; D011720:Pyrazoles / Q000494:pharmacology; D012262:Ribonucleoside Diphosphate Reductase / Q000037:antagonists & inhibitors*; D012264:Ribonucleotide Reductases / Q000037:antagonists & inhibitors*; D013936:Thymidine / Q000494:pharmacology; D014740:Vidarabine / Q000031:analogs & derivatives / Q000494:pharmacology
D003839:Deoxyadenosines; D007546:Isoquinolines; D019384:Nucleic Acid Synthesis Inhibitors; D011720:Pyrazoles; C013118:4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone; C030964:2'-fluoro-2'-deoxyadenosine; D012264:Ribonucleotide Reductases; D012262:Ribonucleoside Diphosphate Reductase; D006005:Phosphorylases; D014740:Vidarabine; D003849:Deoxyguanosine; C000971:2,3-dihydro-1H-imidazo(1,2-b)pyrazole; C024352:fludarabine; D013936:Thymidine; D006918:Hydroxyurea